By Fineline Cube 
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months ended June 30, 2026, alongside key clinical and commercialization progress updates.
Financial Performance Summary
| Metric | H1 2026 | YOY Change (CER) |
|---|---|---|
| Total Consolidated Revenue | USD 278.0m | -4% |
| Total Oncology Revenue | USD 121.4m | +18% |
| Total Oncology In-Market Sales | USD 279.8m | +17% |
| Other Ventures Revenue | USD 116.0m | Prescription drug distribution |
Oncology Commercial Highlights
- ELUNATE (fruquintinib): Sales grew 41% to USD 60.8m, benefiting from expanded National Reimbursement Drug List (NRDL) coverage to include endometrial cancer and approval for renal cell carcinoma (RCC) indication
- SULANDA: Sales surged 45% to USD 18.4m, fueled by upgraded recommendation levels in Chinese Society of Clinical Oncology (CSCO) Guidelines for neuroendocrine tumors (NETs)
- FRUZAQLA (fruquintinib overseas): Ex-U.S. sales grew approximately 70% to USD 68.9m, driven by demand for innovative chemo-free treatment options in metastatic colorectal cancer (mCRC)
Other Revenue Streams
- Other Oncology/Immunology Revenues: USD 40.9m (including USD 18.1m milestone payment from Eli Lilly triggered by second-line RCC approval)
- Full-Year 2026 Guidance: Reaffirmed total Oncology/Immunology consolidated revenue of USD 330m to USD 450m
Strategic Investment Focus
Capitalizing on its strong cash position, HutchMed will accelerate the global development of its ATTC (Antibody-Targeted Therapeutic Conjugate) projects and explore target investment opportunities.
Market Context & Competitive Positioning
- Oncology Market Growth: Despite overall revenue decline, HutchMed’s oncology segment demonstrates strong double-digit growth
- Commercial Strategy Success: NRDL inclusion and guideline recommendations driving significant product adoption
- Global Expansion: FRUZAQLA’s 70% ex-U.S. growth validates international market potential
- Pipeline Development: ATTC platform represents next-generation therapeutic approach with significant commercial potential
Company Statement
HutchMed’s strong oncology performance demonstrates the company’s successful execution of its commercial strategy, with ELUNATE and SULANDA gaining significant market traction through expanded reimbursement coverage and clinical guideline recognition. The 70% growth in FRUZAQLA ex-U.S. sales highlights the global demand for innovative, chemo-free treatment options in metastatic colorectal cancer.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, growth expectations, and business outlook. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, and other risk factors.-Fineline Info & Tech